Source: Novo Nordisk & reported by http://www.prnewswire.co.uk/
MUNICH, September 13, 2016 /PRNewswire/ -- Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly improved glycaemic control compared to placebo, as add-on to basal insulin alone or in combination with metformin, in adults with a mean type 2 diabetes duration of 13 years. Results from SUSTAIN 5 were presented today at the 52nd Annual Meeting of the European Association for the Study of Diabetes (EASD) 2016.
The 30-week trial showed that, from a mean baseline HbA1c of 8.4%, adults treated with 0.5 mg and 1.0 mg semaglutide achieved statistically significant and superior HbA1c reductions of 1.4% and 1.8%, respectively, vs 0.1% reduction with placebo. In addition, more adults treated with 0.5 mg and 1.0 mg semaglutide achieved HbA1c targets compared with placebo: HbA1c <7% (61% and 79% vs 11%) and ≤6.5% (41% and 61% vs 5%). Adults with type 2 diabetes treated with 0.5 mg and 1.0 mg semaglutide achieved superior weight loss vs placebo (3.7 kg and 6.4 kg vs 1.4 kg) from a mean baseline body weight of 91.7 kg. Read more: http://www.prnewswire.co.uk/news-releases/semaglutide-demonstrated-superior-hba1c-reduction-vs-placebo-as-add-on-to-basal-insulin-alone-or-with-metformin-in-adults-with-type-2-diabetes-593219281.html